10-propargyl-10-deazaaminopterin and Mesothelioma

10-propargyl-10-deazaaminopterin has been researched along with Mesothelioma in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bertino, JR; Farooqi, IN; Kathari, YK; Tedeschi, PM	1
Heelan, RT; Kris, MG; Krug, LM; Sirotnak, FM; Venkatraman, E	1
Khokhar, NZ; Rusch, VW; She, Y; Sirotnak, FM	1

Trials

1 trial(s) available for 10-propargyl-10-deazaaminopterin and Mesothelioma

Article	Year
Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2007, Volume: 2, Issue:4 Topics: Aged; Aged, 80 and over; Aminopterin; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Mesothelioma; Middle Aged; Neoplasm Staging; Palliative Care; Pleural Neoplasms; Probability; Prognosis; Risk Assessment; Survival Analysis; Terminally Ill	2007

Article

Year

Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2007, Volume: 2, Issue:4

Topics: Aged; Aged, 80 and over; Aminopterin; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Mesothelioma; Middle Aged; Neoplasm Staging; Palliative Care; Pleural Neoplasms; Probability; Prognosis; Risk Assessment; Survival Analysis; Terminally Ill

2007

Other Studies

2 other study(ies) available for 10-propargyl-10-deazaaminopterin and Mesothelioma

Article	Year
Leucovorin rescue allows effective high-dose pralatrexate treatment and an increase in therapeutic index in mesothelioma xenografts. Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:5 Topics: Aminopterin; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Female; Folic Acid Antagonists; Glutamates; Guanine; Humans; Leucovorin; Mesothelioma; Methotrexate; Mice, Nude; Pemetrexed; Time Factors; Tumor Burden; Vitamin B Complex; Xenograft Model Antitumor Assays	2014
Experimental therapeutics with a new 10-deazaaminopterin in human mesothelioma: further improving efficacy through structural design, pharmacologic modulation at the level of MRP ATPases, and combined therapy with platinums. Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:10 Topics: Adenosine Triphosphatases; Aminopterin; Animals; Anion Transport Proteins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Cycle Proteins; Cell Division; Cisplatin; Drug Design; Fungal Proteins; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Mesothelioma; Methotrexate; Mice; Mice, Nude; Multidrug Resistance-Associated Proteins; Platinum Compounds; Protein Isoforms; Protein Kinases; RNA, Neoplasm; Schizosaccharomyces pombe Proteins; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2001

Article

Year

Leucovorin rescue allows effective high-dose pralatrexate treatment and an increase in therapeutic index in mesothelioma xenografts.

Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:5

Topics: Aminopterin; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Female; Folic Acid Antagonists; Glutamates; Guanine; Humans; Leucovorin; Mesothelioma; Methotrexate; Mice, Nude; Pemetrexed; Time Factors; Tumor Burden; Vitamin B Complex; Xenograft Model Antitumor Assays

2014

Experimental therapeutics with a new 10-deazaaminopterin in human mesothelioma: further improving efficacy through structural design, pharmacologic modulation at the level of MRP ATPases, and combined therapy with platinums.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:10

Topics: Adenosine Triphosphatases; Aminopterin; Animals; Anion Transport Proteins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Cycle Proteins; Cell Division; Cisplatin; Drug Design; Fungal Proteins; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Mesothelioma; Methotrexate; Mice; Mice, Nude; Multidrug Resistance-Associated Proteins; Platinum Compounds; Protein Isoforms; Protein Kinases; RNA, Neoplasm; Schizosaccharomyces pombe Proteins; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2001